Intervention Review

Statins for multiple sclerosis

  1. Jin Wang1,
  2. Yousheng Xiao1,*,
  3. Man Luo1,
  4. Hongye Luo2

Editorial Group: Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group

Published Online: 7 DEC 2011

Assessed as up-to-date: 15 AUG 2011

DOI: 10.1002/14651858.CD008386.pub3

How to Cite

Wang J, Xiao Y, Luo M, Luo H. Statins for multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD008386. DOI: 10.1002/14651858.CD008386.pub3.

Author Information

  1. 1

    The First Affiliated Hospital, Guangxi Medical University, Department of Neurology, Nanning, Guangxi, China

  2. 2

    Guangxi Medical University, Dept. of Epidemiology & Statistics, Nanning, Guangxi, China

*Yousheng Xiao, Department of Neurology, The First Affiliated Hospital, Guangxi Medical University, No. 22, Shuang Yong Lu, Nanning, Guangxi, 530021, China.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 7 DEC 2011


Cited in:


This article has been cited by:

  1. 1
    Jeremy Chataway, Nadine Schuerer, Ali Alsanousi, Dennis Chan, David MacManus, Kelvin Hunter, Val Anderson, Charles R M Bangham, Shona Clegg, Casper Nielsen, Nick C Fox, David Wilkie, Jennifer M Nicholas, Virginia L Calder, John Greenwood, Chris Frost, Richard Nicholas, Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial, The Lancet, 2014, 383, 9936, 2213


  2. 2
    W. Gibson Wood, Walter E. Mΰller, Gunter P. Eckert, Statins and Neuroprotection: Basic Pharmacology Needed, Molecular Neurobiology, 2014, 50, 1, 214